Aquestive Therapeutics (AQST) Scheduled to Post Quarterly Earnings on Tuesday

Aquestive Therapeutics (NASDAQ:AQST) is scheduled to release its earnings data after the market closes on Tuesday, May 7th. Analysts expect Aquestive Therapeutics to post earnings of ($0.09) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings data on Tuesday, March 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.04). The business had revenue of $13.21 million during the quarter, compared to the consensus estimate of $11.79 million. On average, analysts expect Aquestive Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Aquestive Therapeutics Stock Performance

AQST opened at $3.52 on Friday. The firm has a market cap of $320.46 million, a price-to-earnings ratio of -25.14 and a beta of 2.95. The firm’s 50-day simple moving average is $4.25 and its 200-day simple moving average is $2.88. Aquestive Therapeutics has a twelve month low of $1.25 and a twelve month high of $6.23.

Analyst Upgrades and Downgrades

AQST has been the topic of several research analyst reports. Raymond James assumed coverage on shares of Aquestive Therapeutics in a research note on Thursday, March 28th. They set an “outperform” rating and a $7.00 price objective on the stock. JMP Securities increased their price target on Aquestive Therapeutics from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Friday, March 15th. Piper Sandler began coverage on Aquestive Therapeutics in a research report on Thursday, April 11th. They issued an “overweight” rating and a $10.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and set a $9.00 target price on shares of Aquestive Therapeutics in a report on Tuesday, April 30th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $8.00.

Insider Activity

In related news, insider Alexander Mark Schobel sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $6.00, for a total value of $300,000.00. Following the completion of the transaction, the insider now owns 984,476 shares in the company, valued at approximately $5,906,856. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 8.39% of the stock is owned by insiders.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.